- Home
- PLUG vs TARS Comparison
PLUG vs TARS Comparison
Compare PLUG & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | TARS |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLUG | TARS |
|---|---|---|
| Price | $1.87 | $66.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $2.10 | ★ $77.13 |
| AVG Volume (30 Days) | ★ 88.9M | 502.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.55 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $628,814,000.00 | $182,953,000.00 |
| Revenue This Year | $20.45 | $147.68 |
| Revenue Next Year | $23.88 | $50.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 948.62 |
| 52 Week Low | $0.69 | $38.51 |
| 52 Week High | $4.58 | $85.25 |
Technical Indicators
Market Signals| Indicator | PLUG | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 42.48 |
| Support Level | $1.81 | $60.88 |
| Resistance Level | $1.92 | $67.70 |
| Average True Range (ATR) | 0.13 | 3.23 |
| MACD | -0.02 | 0.45 |
| Stochastic Oscillator | 22.02 | 53.49 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.